Curated News
By: NewsRamp Editorial Staff
June 07, 2024
Theriva Biologics Receives FDA Fast Track Designation for VCN-01 in Pancreatic Cancer Treatment
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Theriva Biologics received Fast Track Designation (FTD) from the U.S. FDA for VCN-01, potentially giving the company an advantage in the competitive pharmaceutical market.
- Theriva Biologics is developing oncolytic viruses, such as VCN-01, to selectively kill tumor cells, with ongoing clinical trials to test its effectiveness in treating pancreatic cancer.
- Theriva Biologics' mission is to change patient outcomes by improving cancer therapy, offering hope to patients with difficult-to-treat cancers and potentially increasing survival rates.
- The increasing incidence of pancreatic cancer globally drives the need for innovative treatment options like VCN-01, potentially shaping the future of cancer therapy.
Impact - Why it Matters
The FDA's Fast Track Designation for VCN-01 reflects the urgent need for new treatment options for pancreatic cancer, a leading cause of cancer death globally. This milestone underscores the potential of VCN-01 to improve patient outcomes and reduce mortality. As incidences of pancreatic cancer continue to rise, Theriva Biologics' focus on innovative cancer therapies could have a significant impact on the industry and patient care.
Summary
Theriva™ Biologics (AMEX: TOVX) is a biotech company focused on developing oncolytic viruses to treat cancer. The company recently achieved a significant milestone as the U.S. FDA granted Fast Track Designation to its candidate VCN-01 for the treatment of metastatic pancreatic adenocarcinoma. Theriva Biologics is also rebranding to reflect its evolving focus on oncolytic viruses and cancer therapies.
VCN-01 is part of an ongoing phase 2 clinical trial in combination with standard-of-care chemotherapy for patients with pancreatic cancer. Additionally, the company is developing SYN-004 (ribaxamase) to mitigate adverse outcomes for patients undergoing bone marrow transplant for hematologic cancers.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Theriva Biologics Receives FDA Fast Track Designation for VCN-01 in Pancreatic Cancer Treatment
